Yeo lab:Projects: Difference between revisions
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. | One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. | ||
'''Dr. Yeo’s lab''' will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific research projects include: | |||
*Developing nanoparticles which mimic leukocyte-rolling behavior for tumor targeting. | |||
*Pulmonary drug delivery for cystic fibrosis and pulmonary hypertension therapy. | |||
*Developing sustained delivery systems for macromolecules based on hydrogels and novel microencapsulation techniques. | |||
|}<br style="clear:both" /> | |}<br style="clear:both" /> | ||
Revision as of 12:51, 14 January 2007
|
One of the major obstacles in translating potent drug candidates from bench to bedside is their spatiotemporally adequate delivery. For example, small interfering RNA (siRNA) has been recognized as a promising new class of drugs for viral infections, neurodegenerative diseases, and cancer; however, its therapeutic potential has not been realized because of the instability in circulation and inefficient delivery to the target cells. Target-specific delivery of anti-cancer drugs with minimal side effects on normal tissues has long been a goal for cancer therapy, but their clinical application remains challenging. Dr. Yeo’s lab will focus on developing drug/gene delivery systems which can address these challenges in ‘delivery.’ Specific research projects include:
|
